Previous 10 | Next 10 |
2024-06-05 13:00:00 ET Summary The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in this edition. A number of veteran Seeking Alph...
Data Demonstrates Sustained Safety and Efficacy in Treating Signs and Symptoms of Dry Eye Disease Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE&...
2024-06-03 10:15:02 ET Lake Street analyst issues BUY recommendation for HROW on June 3, 2024 08:56AM ET. The previous analyst recommendation was Buy. HROW was trading at $18.125 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-06-03 10:00:06 ET Brooks O'Neil from Lake Street issued a price target of $25.00 for HROW on 2024-06-03 08:56:00. The adjusted price target was set to $25.00. At the time of the announcement, HROW was trading at $18.125. HROW currently trades -19.22% versus its 52 w...
2024-05-24 12:12:17 ET Summary Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. Th...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24 th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, C...
2024-05-14 13:44:42 ET More on mid-day movers & stocks. JanOne to acquire blockchain financial technology provider ALT 5 Sigma Financial information for JanOne Financial information for Mmtec Seeking Alpha’s Quant Rating on ProKidney Histor...
Harrow Health, Inc. (NASDAQ: HROW) is one of today's top gainers. The company's shares have moved 33.64% on the day to $16.11. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding busi...
2024-05-14 10:48:13 ET Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript May 14, 2024, 08:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen -...
2024-05-14 10:00:29 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Health...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 10:00:07 ET Chase Knickerbocker from Craig-Hallum issued a price target of $30.00 for HROW on 2024-06-21 08:28:00. The adjusted price target was set to $30.00. At the time of the announcement, HROW was trading at $19.93. The overall price target consensus is a...
Harrow Health, Inc. (NASDAQ: HROW) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 13.77% on the day to $20.08. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an op...